이근욱 (서울대학교 의과대학/분당서울대학교병원)님 | 한빛사연구자 > 한빛사

서울대학교 의과대학/분당서울대학교병원

최종업데이트 2025.07.14.

- ( 현재 등록 진행중입니다. )
- 이근욱(서울대학교 의과대학/분당서울대학교병원)
Phase 1b/2 Study of Zanidatamab in Combination with Tislelizumab and Chemotherapy in First-Line HER2-Positive Gastric/Gastroesophageal Junction Adenocarcinoma
- Clin. Cancer Res., Dec 01 2025, | https://doi.org/10.1158/1078-0432.CCR-24-4295
- 2025-12
- 한빛사논문
- 이근욱(서울대학교 의과대학/분당서울대학교병원)
DKN-01 and tislelizumab as second-line therapy in DKK1-high gastroesophageal adenocarcinoma: DisTinGuish trial part B
- Nat. Commun., Published: 10 July 2025 | https://doi.org/10.1038/s41467-025-61420-x
- 2025-07
- 의약학
- 한빛사논문
- 이근욱(분당서울대학교병원, The University of Texas MD Anderson Cancer Center)
Association of Tumor Mutational Burden with Efficacy of Pembrolizumab±Chemotherapy as First-Line Therapy for Gastric Cancer in the Phase III KEYNOTE-062 Study
- Clin. Cancer Res., 2022 Aug 15;28(16):3489-3498 | https://doi.org/10.1158/1078-0432.CCR-22-0121
- 2022-08
- 한빛사논문
Significant Association of Oncogene YAP1 with Poor Prognosis and Cetuximab Resistance in Colorectal Cancer Patients
- Clin. Cancer Res., January 2015, 21(2); 357-64. | DOI: 10.1158/1078-0432.CCR-14-1374
- 2015-01
- 의약학
- 구.추천논문

연구자 ID

저자논문